ストックスクリーナーアプリを入手
1.96
2.49%
-0.05
前日終値:
$2.01
開ける：
$2.12
24時間の取引高:
11.96M
Relative Volume:
2.74
時価総額：
$258.62M
収益：
-
当期純損益:
$-110.78M
株価収益率:
-1.8318
EPS:
-1.07
ネットキャッシュフロー:
$-75.59M
1週間 パフォーマンス:
-40.96%
1か月 パフォーマンス:
-41.84%
6か月 パフォーマンス:
-64.87%
1年 パフォーマンス:
-36.98%
1日の値動き範囲:
$1.76
$2.13
1週間の範囲:
$1.76
$3.36
52週間の値動き範囲:
$1.76
$9.97
Humacyte Inc Stock (HUMA) Company Profile
名前
Humacyte Inc
セクター
電話
919-313-9633
住所
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.96 | 258.62M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-12-11 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-14 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-05-16 | ダウングレード | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 開始されました | Cowen | Outperform |
| 2021-09-24 | 開始されました | Oppenheimer | Outperform |
| 2021-09-22 | 開始されました | BTIG Research | Buy |
| 2021-09-16 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Humacyte Inc (HUMA) 最新ニュース
Shareholders that lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
Humacyte price target lowered to $8 from $10 at BTIG - Yahoo Finance
Humacyte’s Symvess Gains FDA Approval and Launches - TipRanks
Humacyte down following quarterly results, hits record low - Seeking Alpha
Durham biotech defends lead product after concerns surface - The Business Journals
Humacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More Bullish - MSN
Humacyte shares tumble 10% as Q4 loss narrows but revenue remains elusive By Investing.com - Investing.com South Africa
Humacyte shares tumble 10% as Q4 loss narrows but revenue remains elusive - Investing.com India
Earnings call transcript: Humacyte Q4 2024 sees narrower EPS loss, stock edges up - Investing.com India
Humacyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Humacyte Q4 Earnings: 34 Hospitals Eye New FDA-Approved Vascular Treatment - StockTitan
Humacyte responds to media coverage with SEC filing By Investing.com - Investing.com Australia
Humacyte CEO addresses concerns in NYT over FDA approval of Symvess - Investing.com
Humacyte responds to media coverage with SEC filing - Investing.com
Humacyte Defends Symvess Approval Amid FDA Scrutiny - TipRanks
Humacyte Earnings Preview - Benzinga
Durham biotech's stock price drops 30% amid offering, reports about product safety - Triangle Business Journal
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - MSN
Humacyte stock slides on pricing public offering of units to raise $50M - MSN
Humacyte Announces Public Offering to Raise $46.6 Million - TipRanks
Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel (NASDAQ:HUMA) - Seeking Alpha
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy? - MSN
Biggest stock movers Wednesday: GME, HUMA, DLTR, and more (HUMA:NASDAQ) - Seeking Alpha
FDA passes lab-grown blood vessel despite major concerns - Medical Brief
Why Humacyte (HUMA) Stock Is Falling Sharply - Benzinga
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News
Humacyte stock plunges on public offering pricing By Investing.com - Investing.com South Africa
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025 - TradingView
Major Biotech Innovation Updates Expected in Humacyte Q4 Earnings Call - StockTitan
Humacyte stock plunges on public offering pricing - Investing.com
Dollar Tree, GameStop, Humacyte - TradingView
Humacyte tumbles on pricing $50 mln stock offering - TradingView
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - Benzinga
Humacyte Secures $50M Funding: Major Push for SYMVESS Commercialization - StockTitan
Humacyte sets $2 stock offering, aims for $50 million - Investing.com
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - The Manila Times
Humacyte Prices Public Offering Of 25 Million Shares At $2.00 Per Share - Marketscreener.com
Humacyte announces public stock offering for expansion By Investing.com - Investing.com South Africa
Humacyte Shares Plunge After Hours: Here's WhyHumacyte (NASDAQ:HUMA) - Benzinga
Humacyte announces public stock offering for expansion - Investing.com India
Humacyte down 13% amid reports that FDA approved device despite warnings - Seeking Alpha
Humacyte Announces Proposed Public Offering Of Common Stock - Marketscreener.com
Humacyte, Inc. Announces Proposed Public Offering of Common Stock - Yahoo Finance
Humacyte To Present Fourth Quarter And Full Year Financial Results And Provide Corporate Update On March 28, 2025 - Marketscreener.com
Humacyte, Inc. (HUMA) Flat As Market Gains: What You Should Know - MSN
FDA Approved Artificial Blood Vessel Despite Warnings - The New York Times
Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) - Seeking Alpha
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Humacyte, Inc. of Class Action Lawsuit and Upcoming DeadlinesHUMA - ACCESS Newswire
Individual investors who hold 41% of Humacyte, Inc. (NASDAQ:HUMA) gained 11%, institutions profited as well - Simply Wall St
Humacyte Inc (HUMA) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):